에 대한 최신 뉴스 GRAIL (NASDAQ:GRAL) 주식

GRAIL

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.

News

Movers

GRAL

캘리포니아주 멘로파크에 본사를 둔 미국의 생명공학 회사인 그레일(NASDAQ:GRAL)의 주식은 회사가 임상 실험 연구 기업인 퀘스트 다이아그노스틱스(NYSE:DGX)와의 새로운 협업을 발표한 후 수요일 18% 이상 급등 마감했다.

수요일 그레일 주식이 18% 이상 급등 마감: 무슨 일이 있었나?

GRAIL Inc

GRAIL INC COM

The solution harmonizes data from organizations' most mission-critical applications with data engineering and business analytics capabilities, paving the way for next-level innovation and insights.
SAP today also announced a powerful new agent builder capability, so customers can build and deploy their own AI agents alongside SAP's library of ready-to-deploy Joule agents.

SAP Unveils Business Data Cloud With Databricks; Also Announces New Agent Builder Capability

Telsey Advisory Group analyst Joseph Feldman maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Outperform and raises the price target from $70 to $73.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Outperform on Kroger, Raises Price Target to $73

Piper Sandler analyst Alexander Goldfarb downgrades Kite Realty Gr Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRG#NYSE">KRG</a>) from Overweight to Neutral and lowers the price target from $33 to $25.

Downgrades

Piper Sandler Downgrades Kite Realty Gr Trust to Neutral, Lowers Price Target to $25

The partnership will enable Ooredoo to expand its MENA footprint of hyperscale and AI data centre infrastructure, combining the strength of the company's local development and operational track record with Iron Mountain's global operating expertise.
 &nbsp;

Iron Mountain To Take Minority Equity Stake In Ooredoo's Data Centre Company MENA Digital Hub, No Terms Disclosed

Telsey Advisory Group analyst Dana Telsey maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Outperform and maintains $70 price target.

BIRK

Telsey Advisory Group Maintains Outperform on Birkenstock Holding, Maintains $70 Price Target

Supported by today's announcement that Forschungszentrum Jülich (FZJ) is the first high-performance computing (HPC) center in the world to purchase a D-Wave Advantage quantum system, D-Wave expects the new systems offering to drive advanced research and new discoveries in areas such as artificial intelligence (AI) and quantum simulation.
The Company also announced the new "Quantum Uplift" program to address the growing number of customers expressing disappointment with competitor quantum systems that are incapable of solving problems of practical value and lack reliable uptime and availability.&nbsp;

QBTS

D-Wave Quantum Reveals On-Premises Systems Offering; Also Unveils Quantum Uplift Program

Non-Executive Board Chair Nancy E. Cooper will remain on the Brunswick Board and current Board member David E. Everitt will assume the role of Lead Independent Director.
Foulkes was appointed Chief Executive Officer and a member of the Board of Brunswick Corporation in January 2019.

Management

Brunswick Board Elects CEO David M. Foulkes As Chairman Of Board, Effective March 1

Seaport Global analyst Tom Curran downgrades Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) from Buy to Neutral.

ASPN

Seaport Global Downgrades Aspen Aerogels to Neutral

Shares of AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quarter revenue guidance <a href="https://www.benzinga.com/news/earnings/25/02/43676556/applovin-stock-soars-on-q4-earnings-revenue-beat-eps-beat-strong-guidance-and-more">above estimates</a>.
Applovin reported fourth-quarter revenue of $1.37 billion, beating analyst estimates of $1.26 billion, according to Benzinga Pro. The company reported fourth-quarter earnings of $1.73 per share, beating analyst estimates of $1.25 per share.
AppLovin shares jumped 28.9% to $490.10 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Phoenix Motor Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) gained 81.2% to $0.4570 in pre-market trading after the company said third-quarter revenue jumped 1,557% year-over-year to $4.77 million.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) rose 42% to $0.9937 in pre-market trading. Tivic Health Systems shares jumped 198% on Wednesday after the company announced it acquired the exclusive license rights from Statera Biopharma for its Phase III TLR5 agonist entolimod treatment of acute radiation syndrome.</li>
<li>Avinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) shares jumped 45.6% to $0.6701 in pre-market trading.</li>
<li>MGO Global, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) gained 38.5% to $0.6326 in pre-market trading after dipping 24% on Wednesday.</li>
<li>ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) gained 26% to $0.3535 in pre-market following a 7% gain in the previous session.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) shares climbed 24.6% to $80.72 in pre-market trading following better-than-expected fourth-quarter financial results.</li>
<li>Twin Disc, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWIN#NASDAQ">TWIN</a>) gained 19.4% to $11.99 in pre-market trading after dipping 10% on Wednesday.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) gained 15.6% to $64.72 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
<li>CEVA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NYSE">CEVA</a>) gained 8.5% to $34.41 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Aspen Aerogels, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) shares fell 30.6% to $8.15 in pre-market trading after the company issued first-quarter guidance below estimates.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) dipped 27% to $89.34 in pre-market trading after the company reported worse-than-expected quarterly revenue results.</li>
<li>Omega Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) fell 24.6% to $0.1960 in today's pre-market trading after surging 35% on Wednesday. Omega Therapeutics' restructuring committee recently approved a workforce reduction of up to 17 employees for cost-reduction amid a Chapter 11 case and potential asset sale.</li>
<li>NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares fell 24.4% to $0.6363 in pre-market trading. NKGen Biotech shares jumped 122% on Wednesday after the company received FDA Fast Track designation for Troculeucel for the treatment of moderate Alzheimer&#8217;s disease.</li>
<li>Mynaric AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNA#NASDAQ">MYNA</a>) fell 23.7% to $0.4730 in pre-market trading after jumping 134% on Wednesday.</li>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) shares tumbled 20.6% to $8.00 in pre-market trading. Fastly reported a fourth-quarter loss of 3 cents per share, down from earnings of 1 cent per share in the prior year&#8217;s quarter. Quarterly revenue came in at $140.58 million, beating the $138.27 million analyst consensus estimate. Fastly expects first-quarter losses of between 9 cents and 5 cents per share, versus the loss of 1 cent estimate, and revenue in a range of $136 million to $140 million, versus the $137.05 million estimate.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) declined 18.1% to $3.30 in pre-market trading.</li>
<li>Atai Life Sciences N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) fell 14.5% to $2.1800 in pre-market trading after the company announced the pricing of public offering of common shares.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) fell 14.1% to $185.94 in pre-market trading after the company reported fourth-quarter results.</li>
<li>Open Lending Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) shares dipped 13% to $5.02 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

ATAI

AVGR

BROS

CEVA

FSLY

HOOD

LPRO

MGOL

MYNA

NKGN

OMGA

PRPH

RDDT

SLSR

TIVC

TWIN

Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2">First Quarter 2025 Guidance &nbsp;</td>
</tr>
<tr>
<td>Net Revenue:</td>
<td>Decrease 8.5% to 12.5% QoQ, Flat to Up 4.6% YoY</td>
</tr>
<tr>
<td>Gross Margin:</td>
<td>Around 30.5%, depending on final product mix</td>
</tr>
<tr>
<td>Profit:</td>
<td>9.0 cents to 11.0 cents per diluted ADS, Up 26% to 54% YoY&nbsp;&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Guidance

HIMX

Himax Technologies Expects Q1 Revenue Growth Of Flat To 4.6% YoY Vs $200.7M Est, EPADS Of $0.09-$0.11 Vs $0.08 Est

TD Securities analyst Andrew Charles maintains Dutch Bros (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) with a Buy and raises the price target from $65 to $89.

TD Securities Maintains Buy on Dutch Bros, Raises Price Target to $89

<h2>Nissan Motor Co., Ltd. ("Nissan") and Honda Motor Co., Ltd. ("Honda") , today agreed to terminate the MOU signed on December 23 last year for consideration of a business integration between the two companies.</h2>
https://global.honda/en/newsroom/news/2025/c250213aeng.html

NSANY

Earlier Nissan, Honda Announced Termination Of MOU For Consideration Of Business Integration

Earnings

Himax Technologies Q4 EPS $0.14 Beats $0.10 Estimate, Sales $237.22M Beat $221.09M Estimate

Needham analyst Scott Berg reiterates Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) with a Buy and maintains $14 price target.

Reiteration

SMWB

Needham Reiterates Buy on Similarweb, Maintains $14 Price Target

Needham analyst Charles Shi reiterates Camtek (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>) with a Buy and maintains $110 price target.

CAMT

Needham Reiterates Buy on Camtek, Maintains $110 Price Target

Needham analyst Chris Pierce maintains Sonic Automotive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>) with a Buy and raises the price target from $74 to $100.

Needham Maintains Buy on Sonic Automotive, Raises Price Target to $100

Evercore ISI Group analyst Shweta Khajuria downgrades Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) from Outperform to In-Line and lowers the price target from $135 to $90.

Evercore ISI Group Downgrades Trade Desk to In-Line, Lowers Price Target to $90

Macro Economic Events

Econ #s

Economics

Eurozone Industrial Production (MoM) For December -1.1% Vs. -0.6% Est.; 0.4% (Revised) Prior

Sen. Mitch McConnell (R-Ky.) expressed his concerns over President Donald Trump&#8217;s tariff policies, warning that they could trigger a trade war and subsequently <a href="https://www.benzinga.com/25/02/43616261/trumps-punitive-tariffs-could-lead-to-us-job-losses-warns-former-ambassadorwere-in-for-a-bit-of-bad-news-in-the-near-term">inflate prices for consumers</a> and businesses in the U.S.
What Happened: McConnell&#8217;s apprehensions were voiced in an op-ed published in Louisville&#8217;s Courier-Journal, as reported by <a href="https://www.cnbc.com/2025/02/12/trump-mcconnell-tariffs-trade-war-kentucky.html">CNBC</a> on Wednesday. The Kentucky Senator expressed that Trump&#8217;s &#8220;aggressive proposals leave big, lingering concerns for American industry and workers.&#8221;
Trump, well known for his support of tariffs, recently implemented widespread import duties on Canada, Mexico, and China, along with additional tariffs on steel and aluminum imports. Though he postponed the tariffs on Mexico and Canada for a month, the delay is scheduled to expire in the first week of March.
&#8216;In his op-ed, McConnell acknowledged the necessity for America&#8217;s closest neighbors to take significant action on the border crisis. However, he firmly asserted that &#8220;tariffs are bad policy.&#8221; In his op-ed, McConnell acknowledged the necessity for America&#8217;s closest neighbors to take significant action on the border crisis. However, he firmly asserted that &#8220;tariffs are bad policy.&#8221;
He also expressed concerns over the possible effects of Trump&#8217;s protectionist policies on Kentucky, considering the state&#8217;s reliance on global trade for its farming, auto, and bourbon whiskey industries.
SEE ALSO: <a href="https://www.benzinga.com/25/02/43682491/elon-musks-doge-dedication-sparks-tesla-brand-deterioration-as-ev-maker-drops-20-after-trump-inauguration-dan-ives-says-bark-way-worse-than-the-bite">Judge Blocks Trump&#8217;s Bold USAID Layoff Plan, Saving 2,200 Workers – Major Setback for &#8216;America First&#8217; Agenda?</a>
Why It Matters: McConnell&#8217;s criticism of Trump&#8217;s tariff plans is significant, as he is one of the few Republicans to publicly oppose the President&#8217;s trade war with the U.S.&#8217;s biggest trading partners. "Blanket tariffs make it more expensive to do business in America, driving up costs for consumers across the board," cautioned McConnell. 
Market analyst&nbsp;Peter Schiff&nbsp;echoed McConnell as he warned about the ripple effect: "Everything that American companies manufacture or build that requires steel or aluminum, such as cars, aircraft, appliances, and houses will cost more.&#8221;
Shares of steel companies <a href="https://www.benzinga.com/content/43562452/3-steel-stocks-to-gain-strength-as-tariffs-reshape-the-market">cheered on the announcement </a>amid hopes of increased domestic demand. United States Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) climbed over 6% in the past month while Steel Dynamics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) surged more than 7% in the same period.
Meanwhile, Goldman Sachs stated, &#8220;The models for earnings-per-share and valuations indicate the fair value of the S&amp;P 500 could decline 5% in the near term, should sustained US tariffs like those recently discussed take place.&#8221; added that the uncertainty surrounding the impact of the trade war could lower the forward 12-month price-to-earnings ratio by approximately 3%.
READ MORE: <a href="https://www.benzinga.com/25/02/43682491/elon-musks-doge-dedication-sparks-tesla-brand-deterioration-as-ev-maker-drops-20-after-trump-inauguration-dan-ives-says-bark-way-worse-than-the-bite">Elon Musk&#8217;s DOGE Dedication Sparks Tesla &#8216;Brand Deterioration&#8217; As EV Maker Drops 20% After Trump Inauguration — Dan Ives Says &#8216;Bark Way Worse Than The Bite&#8217;</a>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

STLD

Mitch McConnell Criticizes Trump's Tariff Plans, Warns Of Potential Price Hike: 'Big, Lingering Concerns For American Industry And Workers'

Piper Sandler analyst Brent Bracelin maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Neutral and raises the price target from $640 to $808.

HUBS

Piper Sandler Maintains Neutral on HubSpot, Raises Price Target to $808

The company sees 2024 Galleri sales of $107M-$110M. Grail (GRAL) disclosed that it plans to present a corporate update and preliminary financial in...

Grail sees 2025 U.S. Galleri sales up 20%-30%

Grail (GRAL) in conference presentation slides reported a cash balance of $767M as of December 31, 2024. The company sees cash runway into 2028. Pu...

Grail reports cash balance of $767M, sees runway into 2028

Grail (GRAL) disclosed that it plans to present a corporate update and preliminary financial information for the quarter and year ended December 31...

Grail sees 2024 revenue $124M-$126M, consensus $120.62M

Grail 2024 revenue guidance range above consensus

GRAIL: Cash Burn And Commercialization Timeline Are Problematic

It's Trump's Market, And We're Living In It, Market Pushes Up And Consolidates For Next Leg

09:37 EST Grail (GRAL) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving br...

Grail Inc trading halted, volatility trading pause

09:47 EST Grail (GRAL) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Tr...

Grail Inc trading resumes

Grail (GRAL) and Quest Diagnostics (DGX) announced the initial phase of a program to improve provider access to GRAIL's Galleri multi-cancer early ...

Grail and Quest Diagnostics announces initial phase of MCED test program

GRAIL teams up with Quest to widen access to Galleri cancer test

CRWD

ILMN

OKLO

Press Releases

GRAIL to Announce Third Quarter 2024 Financial Results

GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

GRAIL Reports Third Quarter 2024 Financial Results

GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

GRAIL to Participate in Upcoming Investor Conferences

Offerings

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology

GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System

GRAIL to Announce Fourth Quarter 2024 Financial Results

DSNKY

TYO:4568

Ardelyx

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

89bio

Immunocore Holdings plc - American Depositary Shares

Immunocore Hldgs

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

MiMedx Group

MannKind

Myriad Genetics

Nurix Therapeutics

Novavax

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Arcus Biosciences

Replimune Group

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Xencor

Morgan Stanley

캘리포니아주 멘로파크에 본사를 둔 미국의 생명공학 회사인 그레일(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>)의 주식은 회사가 임상 실험 연구 기업인 퀘스트 다이아그노스틱스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>)와의 새로운 협업을 발표한 후 수요일 18% 이상 급등 마감했다.
이번 파트너십은 제공자들이 <a href="https://www.benzinga.com/pressreleases/25/01/n42964119/patient-reported-outcomes-for-grails-galleri-multi-cancer-early-detection-blood-test-published-in-">갈레리(Galleri) 다중암 조기 검출 테스트</a>에 더 쉽게 접근할 수 있도록 하는 것을 목표로 한다.
알아야 할 사항: 이번 조치는 검사 주문 과정을 간소화하고 퀘스트의 전국 네트워크를 통해 가용성을 확장할 것으로 기대되지만, 투자자 반응은 그레일의 사업에 미치는 즉각적인 영향에 대한 우려를 나타낸다.
그레일과 퀘스트 다이아그노스틱스는 의사들이 퀘스트의 연결 시스템을 통해 갈레리 테스트를 직접 주문할 수 있는 파트너십의 초기 단계를 공개했다. 이 통합을 통해 500,000명 이상의 제공자가 다른 혈액 검사와 마찬가지로 퀘스트의 쿼텀(Quanum) 실험실 포털과 900개 이상의 전자 건강 기록 시스템을 통해 원활하게 테스트를 요청할 수 있다. 환자들은 테스트 키트를 혈액 채취 약속에 가져갈 필요 없이 퀘스트의 7,400개 위치 중 어느 곳에서나 테스트를 받을 수 있다.
그레일의 사장 조쉬 오프먼(Josh Ofman)은 이 확장의 중요성을 강조하며 조기 발견이 암 치료 결과를 개선하는 데 중요하다고 언급했다.
그는 다섯 가지 암에 대해서만 검진이 확립되어 있는 반면, 암 관련 사망자의 거의 70%는 권장 검진 테스트가 없는 암에서 발생한다고 지적했다. 갈레리 테스트를 정기 검사에 통합함으로써 그레일과 퀘스트는 이 격차를 해소하고 조기 발견을 더 쉽게 접근할 수 있도록 하려 한다.
퀘스트의 수석 부사장 마크 가드너(Mark Gardne)는 이번 협력이 2021년 이후 진행해 온 테스트 접근성 확장 노력을 바탕으로 한다고 강조했다. 그는 새로운 주문 프로세스가 의료 제공자 간의 채택을 간소화하여 갈레리를 표준 암 검진 프로토콜에 통합하기 쉽게 만들 것이라고 밝혔다.
갈레리 테스트는 혈류에서 암 신호를 감지하여 종양이 떨어뜨린 DNA 조각을 식별함으로써 여러 유형의 암을 증상이 나타나기 전에 비침습적으로 선별할 수 있는 방법을 제공한다. 이 테스트는 처방전 전용이며, 50세 이상의 고위험 성인에게 권장된다.
주가 동향: 그레일의 주식은 수요일 18.43% 급등한 39.26달러에 마감되었다.
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-779657" style="width: 478px; height: auto;" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12154323/Screenshot-2025-02-12-at-15.42.59-1024x523.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12154323/Screenshot-2025-02-12-at-15.42.59-1024x523.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12154323/Screenshot-2025-02-12-at-15.42.59-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12154323/Screenshot-2025-02-12-at-15.42.59-768x393.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12154323/Screenshot-2025-02-12-at-15.42.59.png 1536w" alt="" width="1024" height="523" /></a></figure>
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43673047/gilead-ups-2025-outlook-eyes-lenacapavir-launch-for-hiv-prevention">길리어드, 2025 전망 상향 조정, 레나카파비르 HIV 예방 출시 목표</a></li>
</ul>
이미지 출처: Shutterstock.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

GRAIL

뉴스

에 대한 최신 뉴스 GRAIL (NASDAQ:GRAL) 주식

수요일, 2월 12, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌